Elan Shares Climb on $3.25B Biogen's Tysabri Deal

Feb. 6 (Bloomberg) -- Bloomberg's Caroline Hyde reports on what is next for Elan Corp. as Biogen Idec Inc. agreed to acquire the company's stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties. She speaks on Bloomberg Television's "The Pulse."
Can Washington Fix Puerto Rico's Mounting Debt Crisis?
32:04 - Eurasia Group's Corey Boles discusses Puerto Rico's mounting debt crisis with Bloomberg's Mark Crumpton and Matt Miller on "Bloomberg Markets." (Source: Bloomberg)
  • Apple Shares Down to Lowest Level Since February
  • The Winners and Losers of Clean Energy
  • How Nasdaq Is Making Access to Capital Easier